Drug Profile
VCN 01
Alternative Names: VCN-01Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator VCN Biosciences
- Developer AstraZeneca; Theriva Biologics; VCN Biosciences
- Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma
- Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
- Phase I Brain cancer; Ovarian cancer
- No development reported Solid tumours
Most Recent Events
- 08 Apr 2024 Pharmacodynamics data from preclinical studies in Pancreatic cancer released by Theriva Biologics
- 07 Feb 2024 Independent Data Monitoring Committee (IDMC) recommends the continuation of enrollment as planned in the phase IIb VIRAGE trial for Pancreatic cancer (Adjunctive therapy)
- 07 Feb 2024 Adverse events data from the phase IIb VIRAGE trial in Pancreatic cancer released by Theriva Biologics